The original Gabriella Miller Kids First Act was signed into law in 2014. Without taxpayer funding, this Act has been a huge success. Because of this legislation, for the past six years, the National Institutes of Health has been able to provide research grants across the country to investigate childhood cancer and structual birth defects. In addition, NIH has been able to develop a comprehensive shared-data resource for scientists researching the majority of pediatric cancers and structural birth defects, and supported development of computational tools to analyze these large, complex genomic, and clinical data sets. The original Act will expire in four years.
A new funding source has been found that will enable NIH to continue and expand the vital work done for childhood cancer and birth defects. Again, like the original Act, this funding source will not require any taxpayer funding.
No Appropriations Needed – No Taxpayer Funding Required
Here’s how the new Gabriella Miller Kids First Act 2.0 will create more research for childhood cancer and rare pediatric diseases: Under the Food, Drug, and Cosmetic Act, related companies under this act that violate its laws must pay fines. Under the new Kids First 2.0 Act, the fines are collected and transferred to the National Institutes of Health (NIH), which funds the existing GMKF Pediatric Research Initiative Fund. The new HR 6556 Gabriella Miller Kids First Act 2.0 is expected to generate much more funding. The Gabriella Miller Kids First Research Act 2.0 (H.R. 6556) would redirect penalties levied against the pharmaceutical companies by the U.S. Securities and Exchange Commission (SEC) for violating the existing Foreign Corrupt Practices Act (FCPA). The funds from the penalties would be transferred to the Kids First Pediatric Research Program (Kids First) at the National Institutes of Health (NIH). There have been consistent and large civil sanctions leveraged against pharmaceutical companies since 2013 – hundreds of millions of dollars from six violations alone. With this legislation, penalties from pharmaceutical companies that break the law would be channeled directly to critical medical research for children.
Please consider joining your other colleagues in cosponsoring H.R. 6556- Gabriella Miller Kids First Research Act 2.0. Additional information can be obtained here.
Ellyn Miller, always Gabriella’s Mom